Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1008

2.

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483.

PMID:
16861090
3.
4.

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.

Derosa G, Cicero AF, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R.

Clin Ther. 2005 Sep;27(9):1383-91.

PMID:
16291411
5.

Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin.

Derosa G, Franzetti I, Gadaleta G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Jun;17(3):143-50.

PMID:
15334791
6.

Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.

Derosa G, Salvadeo SA, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, Cicero AF.

Curr Med Res Opin. 2009 Mar;25(3):607-15. doi: 10.1185/03007990802711024 .

PMID:
19232035
7.

Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.

Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G.

Diabetes Metab. 2005 Jun;31(3 Pt 1):255-60.

8.
9.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
10.

Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.

Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.

Pharmacotherapy. 2005 May;25(5):637-45.

PMID:
15899724
11.

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.

Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Salvadeo S, Ciccarelli L, Fogari R.

Diabetes Res Clin Pract. 2005 Jul;69(1):5-13.

PMID:
15955382
13.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
14.
15.

Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.

Derosa G, Gaddi AV, Piccinni MN, Salvadeo S, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, Cicero AF.

Diabetes Obes Metab. 2006 Mar;8(2):197-205.

PMID:
16448524
16.

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

Rosenstock J, Samols E, Muchmore DB, Schneider J.

Diabetes Care. 1996 Nov;19(11):1194-9.

PMID:
8908379
17.

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin.

Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R.

Diabetes Res Clin Pract. 2003 Jun;60(3):161-9.

PMID:
12757988
18.
19.

Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride.

Derosa G, Cicero AF, Dangelo A, Gaddi A, Ragonesi PD, Piccinni MN, Salvadeo S, Ciccarelli L, Pricolo F, Ghelfi M, Ferrari I, Montagna L, Fogari R.

Hypertens Res. 2005 Nov;28(11):917-24.

PMID:
16555581
20.

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.

Metabolism. 2008 Nov;57(11):1552-7. doi: 10.1016/j.metabol.2008.06.010.

PMID:
18940393
Items per page

Supplemental Content

Support Center